• 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 2
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 3
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 4
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451459.
  • 5
    Pawlotsky JM. Treating hepatitis C in “difficult-to-treat” patients. N Engl J Med 2004; 351: 422423.
  • 6
    Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang H, et al. The novel nucleoside analogue R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006; 281: 37933799.
  • 7
    Robson R, Berns H, Brandl M, Fettner S, Haznedar J, Hill G, et al. Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting HCV polymerase: results from a phase 1 single dose escalation trial in healthy subjects [Abstract]. Clin Pharmacol Ther 2007; 81( Suppl 1): S98.
  • 8
    Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non nucleosides, but not to nucleosides, polymerase inhibitors among untreated patients. J Antimicrobial Chemotherapy, March 20, 2008. E-pub ahead of print.
  • 9
    Jiang WR, Symons J, Cammack N, Klumpp K. R1479, a novel nucleoside analog and potent inhibitor of HCV replication, does not affect ribavirin-induced hemolysis and erythrocyte fragility in vitro. J Hepatol 2007; 46( Suppl 1): S228.
  • 10
    Godofsky E, Afdhal N, Rustgi V, Shick L, Duncan L, Zhou X-J, et al. First clinical results for a novel antiviral treatment for hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics and antiviral activity of NM283 [Abstract 96]. J Hepatol 2004; 40( Suppl 1): 35.
  • 11
    Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures [Abstract LB-03]. HEPATOLOGY 2004; 40( Suppl 1): 726A.
  • 12
    Chandra P, Raible D, Harper D, Speth J, Villano S, Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study [Abstract 1]. Gastroenterology 2006; 130( Suppl 2): A1.
  • 13
    Le Pogam S, Jiang W, Leveque V, Rajyaguru S, Ma H, Kang H, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006; 351: 349359.
  • 14
    Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Van Vliet A, Van De Wetering De RooiJ J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 15
    Villano S, Howe A, Raible D, Harper D, Speth J, Bichier G. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment naive HCV-infected patients [Abstract 1127]. HEPATOLOGY 2006; 44( Suppl 1): 607A608A.